Case Report: No radiographic evidence of disease for 45 months in a patient with recurrent clear cell renal cell carcinoma treated with third-line combination therapy utilizing toripalimab and axitinib
Renal cancer is estimated to have accounted for 2.4% of all incident cancer cases worldwide in 2018. Renal cell carcinoma (RCC) is the most prevalent adult renal cancer, with the clear cell subtype accounting for 75-85% of cases and displaying pronounc…